Segment & Geographic Data
Quant-Grade Normalized Data
API & CSV Delivery
Icecure Medical Ltd's Business Segments
Icecure Medical Ltd's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of 2025 ((Dec 31 2025))
Reportable Segments
-
Largest Segment
-
Total Revenue
$ 3
Regions Reported
1
Annual Results
Revenue Share by Region -
- Other Countries57.3%
Revenue by Geographic Region -
| Region | Revenue (Millions) | % of Total |
|---|---|---|
| Other Countries | $ 2 | 57.3% |
Revenue by Product & Service Category -
- Disposables60.8%
- Systems39.2%
- Exclusive Distribution Agreement0%
Revenue by Product & Service Category -
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Disposables | $ 2 | 60.8% |
| Systems | $ 1 | 39.2% |
| Exclusive Distribution Agreement | - | 0% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Icecure Medical Ltd
Icecure Medical Ltd. is an innovative medical technology company specializing in cryoablation, a minimally invasive treatment for various types of tumors and other medical conditions. The company was founded in 2006 and is based in Caesarea, Israel.
Icecure's flagship product, called IceSense3, is a unique cryoablation system that uses the power of extreme cold to destroy targeted tissue. This system has been approved by regulatory authorities in the United States, Europe, Asia, and other countries, making it accessible to a global market. The IceSense3 system has been successfully used in thousands of procedures worldwide, providing patients with a safe and effective alternative to traditional surgical interventions.
The key advantage of the IceSense3 system is its ability to precisely ablate tumors while protecting surrounding healthy tissue. The procedure works by inserting a thin needle-like probe into the tumor site, which then releases extremely cold temperatures (-170 degrees Celsius or -274 degrees Fahrenheit) to freeze the tumor. This freezing process causes cells within the tumor to die, leading to its shrinkage and eventual elimination. Unlike traditional surgery or radiation therapy, cryoablation does not require incisions, reducing the risk of complications, pain, and scarring for the patient.
Icecure Medical Ltd. has dedicated significant efforts to research and development, resulting in a robust portfolio of clinical evidence supporting the efficacy and safety of cryoablation. The company collaborates with renowned medical institutions globally to validate its technology and expand the range of conditions that can be treated with cryoablation. Currently, the IceSense3 system is used primarily for treating breast cancer, kidney cancer, liver cancer, and benign breast tumors, but there is ongoing research exploring its potential application in other areas, such as lung cancer, bone tumors, and prostate cancer.
Additionally, Icecure Medical Ltd. provides comprehensive training and support programs to healthcare professionals and institutions to ensure proper usage and optimal patient outcomes. The company's team of experienced professionals, including engineers, scientists, and medical experts, work closely with physicians to develop personalized treatment plans and offer technical assistance whenever necessary.
Icecure Medical Ltd. continues to invest in innovation and expanding its product offerings. In recent years, the company introduced the IceSense3 CryoProbe, which allows for multiple ablations in one session, enabling more efficient treatment delivery. The CryoProbe's versatility permits the treatment of larger tumors and increases the potential for patient eligibility. By actively pursuing collaborations and partnerships, Icecure aims to further enhance its cryoablation technology and explore new therapeutic areas.
Notably, Icecure Medical Ltd. is committed to complying with strict regulatory standards and adhering to ethical business practices. The company prioritizes patient safety, clinical excellence, and the overall improvement of healthcare outcomes. Icecure's dedication to continuous innovation and its proven track record in cryoablation technologies position it as a leader in the field, contributing to advancements in cancer treatment and improving the lives of patients worldwide.
Icecure's flagship product, called IceSense3, is a unique cryoablation system that uses the power of extreme cold to destroy targeted tissue. This system has been approved by regulatory authorities in the United States, Europe, Asia, and other countries, making it accessible to a global market. The IceSense3 system has been successfully used in thousands of procedures worldwide, providing patients with a safe and effective alternative to traditional surgical interventions.
The key advantage of the IceSense3 system is its ability to precisely ablate tumors while protecting surrounding healthy tissue. The procedure works by inserting a thin needle-like probe into the tumor site, which then releases extremely cold temperatures (-170 degrees Celsius or -274 degrees Fahrenheit) to freeze the tumor. This freezing process causes cells within the tumor to die, leading to its shrinkage and eventual elimination. Unlike traditional surgery or radiation therapy, cryoablation does not require incisions, reducing the risk of complications, pain, and scarring for the patient.
Icecure Medical Ltd. has dedicated significant efforts to research and development, resulting in a robust portfolio of clinical evidence supporting the efficacy and safety of cryoablation. The company collaborates with renowned medical institutions globally to validate its technology and expand the range of conditions that can be treated with cryoablation. Currently, the IceSense3 system is used primarily for treating breast cancer, kidney cancer, liver cancer, and benign breast tumors, but there is ongoing research exploring its potential application in other areas, such as lung cancer, bone tumors, and prostate cancer.
Additionally, Icecure Medical Ltd. provides comprehensive training and support programs to healthcare professionals and institutions to ensure proper usage and optimal patient outcomes. The company's team of experienced professionals, including engineers, scientists, and medical experts, work closely with physicians to develop personalized treatment plans and offer technical assistance whenever necessary.
Icecure Medical Ltd. continues to invest in innovation and expanding its product offerings. In recent years, the company introduced the IceSense3 CryoProbe, which allows for multiple ablations in one session, enabling more efficient treatment delivery. The CryoProbe's versatility permits the treatment of larger tumors and increases the potential for patient eligibility. By actively pursuing collaborations and partnerships, Icecure aims to further enhance its cryoablation technology and explore new therapeutic areas.
Notably, Icecure Medical Ltd. is committed to complying with strict regulatory standards and adhering to ethical business practices. The company prioritizes patient safety, clinical excellence, and the overall improvement of healthcare outcomes. Icecure's dedication to continuous innovation and its proven track record in cryoablation technologies position it as a leader in the field, contributing to advancements in cancer treatment and improving the lives of patients worldwide.
Icecure Medical Ltd is a biotechnology company specializing in innovative solutions for the treatment of tumors and other medical conditions using its proprietary method of cryoablation. The company primarily focuses on developing and commercializing medical devices that utilize cryotherapy, a treatment approach that involves the application of extreme cold to destroy abnormal tissues such as tumors.
Segments
Icecure Medical operates primarily within the healthcare and biotechnology sector, focusing on oncological treatments. Its key segments include:
1. Oncology Treatments: This segment includes the development and commercialization of cryoablation systems specifically designed to treat tumors in various locations, including breast, liver, lung, and kidney cancers. The technology offers a minimally invasive option for patients who may not be suitable candidates for traditional surgical procedures.
2. Research and Development: This segment involves ongoing clinical trials and research into the efficacy and safety of ice therapy treatments. The company invests significantly in R&D to expand the applications of its technology and adapt it for different types of cancers or other medical conditions.
3. Commercial Sales and Distribution: This includes the strategies and efforts to market Icecures cryoablation products globally, working with healthcare providers, hospitals, and clinics to introduce this innovative therapy.
Products
Icecure Medicals flagship product is the ProSys Cryoablation System, which is designed for a range of applications in the treatment of tumors. Key features and aspects of this product include:
- Minimally Invasive Procedure: The ProSys system allows physicians to perform procedures that require less recovery time and have fewer complications compared to traditional surgical interventions.
- Real-Time Monitoring: The system includes advanced imaging capabilities, enabling clinicians to monitor the cryoablation process in real time, ensuring the precise targeting of the tumor while minimizing damage to surrounding healthy tissues.
- Versatility: The ProSys Cryoablation System is designed to treat various cancers, making it a versatile solution within oncological therapies.
- FDA Approval and CE Mark: The product has received regulatory approvals, ensuring compliance with international safety and efficacy standards, which aids in building trust among healthcare professionals and patients.
Services
In addition to its products, Icecure Medical offers various services to support physicians, healthcare providers, and patients. These include:
1. Training and Education: Icecure provides comprehensive training programs for healthcare professionals to ensure they are proficient in using the ProSys Cryoablation System effectively. This includes hands-on workshops, online training modules, and educational webinars focusing on the latest developments in cryoablation techniques.
2. Clinical Support Services: The company offers clinical support to healthcare facilities implementing its technologies, including assistance with patient assessments, treatment planning, and follow-up care protocols.
3. Research Collaboration: Icecure actively collaborates with research institutions and clinical centers to gather clinical data, conduct studies, and further validate the safety and efficacy of its cryoablation technology in various cancer treatments.
4. Customer Support: Icecure maintains a dedicated customer service team to assist healthcare providers with any technical or operational issues related to their products. This includes maintenance of the cryoablation systems, troubleshooting, and logistical support during procedures.
Conclusion
Icecure Medical Ltd continues to innovate within the oncology space, providing advanced solutions for tumor treatment through its proprietary cryoablation technology. Its focus on minimally invasive procedures, supported by a robust suite of services and training offerings, positions Icecure as a leading player in the development of contemporary oncological treatments. Through ongoing research and development, Icecure aims to expand its portfolio and reach more patients, enhancing the overall standard of care in cancer treatment.
Segments
Icecure Medical operates primarily within the healthcare and biotechnology sector, focusing on oncological treatments. Its key segments include:
1. Oncology Treatments: This segment includes the development and commercialization of cryoablation systems specifically designed to treat tumors in various locations, including breast, liver, lung, and kidney cancers. The technology offers a minimally invasive option for patients who may not be suitable candidates for traditional surgical procedures.
2. Research and Development: This segment involves ongoing clinical trials and research into the efficacy and safety of ice therapy treatments. The company invests significantly in R&D to expand the applications of its technology and adapt it for different types of cancers or other medical conditions.
3. Commercial Sales and Distribution: This includes the strategies and efforts to market Icecures cryoablation products globally, working with healthcare providers, hospitals, and clinics to introduce this innovative therapy.
Products
Icecure Medicals flagship product is the ProSys Cryoablation System, which is designed for a range of applications in the treatment of tumors. Key features and aspects of this product include:
- Minimally Invasive Procedure: The ProSys system allows physicians to perform procedures that require less recovery time and have fewer complications compared to traditional surgical interventions.
- Real-Time Monitoring: The system includes advanced imaging capabilities, enabling clinicians to monitor the cryoablation process in real time, ensuring the precise targeting of the tumor while minimizing damage to surrounding healthy tissues.
- Versatility: The ProSys Cryoablation System is designed to treat various cancers, making it a versatile solution within oncological therapies.
- FDA Approval and CE Mark: The product has received regulatory approvals, ensuring compliance with international safety and efficacy standards, which aids in building trust among healthcare professionals and patients.
Services
In addition to its products, Icecure Medical offers various services to support physicians, healthcare providers, and patients. These include:
1. Training and Education: Icecure provides comprehensive training programs for healthcare professionals to ensure they are proficient in using the ProSys Cryoablation System effectively. This includes hands-on workshops, online training modules, and educational webinars focusing on the latest developments in cryoablation techniques.
2. Clinical Support Services: The company offers clinical support to healthcare facilities implementing its technologies, including assistance with patient assessments, treatment planning, and follow-up care protocols.
3. Research Collaboration: Icecure actively collaborates with research institutions and clinical centers to gather clinical data, conduct studies, and further validate the safety and efficacy of its cryoablation technology in various cancer treatments.
4. Customer Support: Icecure maintains a dedicated customer service team to assist healthcare providers with any technical or operational issues related to their products. This includes maintenance of the cryoablation systems, troubleshooting, and logistical support during procedures.
Conclusion
Icecure Medical Ltd continues to innovate within the oncology space, providing advanced solutions for tumor treatment through its proprietary cryoablation technology. Its focus on minimally invasive procedures, supported by a robust suite of services and training offerings, positions Icecure as a leading player in the development of contemporary oncological treatments. Through ongoing research and development, Icecure aims to expand its portfolio and reach more patients, enhancing the overall standard of care in cancer treatment.